Day: April 27, 2021

Please see the full report in PDF format Attachment2021_21_Q12021_CompanyAnnouncement

Dato: 27. april 2021 Årets meddelelse nr.: 14 Opdatering af årsrapporten skal ses i sammenhæng med, at revisor i den oprindelige årsrapport for 2020, offentliggjort den 31. marts 2021, indikerede at Blue Vision A/S’ gælds- og likviditetssituation medførte en væsentlig usikkerhed, hvilket skabte betydeligt tvivl om Selskabets evne til at fortsætte driften. Med henvisning hertil tildelte Nasdaq Copenhagen A/S den 6. april 2021 Blue Vision A/S observationsstatus. Blue Vision A/S gav i resumeet til årsrapporten 2020 blandt andet oplysning om, at situationen ville blive forsøgt imødekommet i medfør af yderligere kreditorforhandlinger og kapitalfremskaffelse, herunder overvejelser og sonderinger om optagelse af konvertible lån. Blue Vision A/S gav i selskabsmeddelelse af i går den 26. april 2021 information om en række gennemførte tiltag. Da...

Press ReleaseU.S. Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene Bunod in Normal Tension GlaucomaApril 27, 2021 – release at 7:30 am CETSophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the U.S. patent covering the use of latanoprostene bunod for the treatment of normal tension glaucoma. Latanoprostene bunod ophthalmic solution, 0.024%, is commercialized as VYZULTA®, for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication. Normal tension glaucoma, also known as low tension or normal pressure glaucoma, is a form of glaucoma...

2021 First quarterPress release – Paris, April 27th, 2021 Strong performance in APACEurope still impacted by lockdowns and restrictive measuresEarly signs of recovery in the AmericasQ1 2021 Sales: €223.9 million, down -2.1% as reported; -0.6% on an organic1 basis Strong performance in APAC (+64.6%1) driven by a double-digit growth in Mainland China: +92.6%1, and +26% vs. Q1 2019 Lockdowns and restrictive measures continue to weigh on performance in Europe Early signs of a rebound in demand and traffic in the Americas, notably in the US Digital sales continue to grow strongly: +38.9% Expansion in Asia // Continued network optimization in France: -33 POS net closings (vs.-8 in Q1 2020) Focus maintained on tight cost and cash managementCommenting on those results, Daniel Lalonde, CEO of SMCP, stated: “Over the quarter, our sales...

1ertrimestre 2021Communiqué – Paris, le 27 avril 2021 Bonne performance en APACImpact des mesures gouvernementales et des fermetures en EuropePremiers signes de reprise en AmériqueChiffre d’affaires T1 2021 : 223,9 M€, en baisse de -2,1% ; -0,6% en organique1 Bonne performance en région APAC (+64,6%1) portée par une croissance à deux chiffres en Chine continentale : +92,6%, et +26% par rapport à T1 2019 Les fermetures et mesures gouvernementales continuent de peser sur la performance en Europe Premiers signes d’un rebond de la demande et du trafic en région Amériques, notamment aux Etats-Unis Les ventes e-commerce poursuivent leur forte croissance : +38,9% Expansion en Asie // Poursuite du plan d’optimisation France : – 33 fermetures nettes de POS (contre -8 au T1 2020) Maintien d’une gestion rigoureuse des coûts et de la...

Company Announcement No. 883 The Board of Directors of DSV Panalpina A/S has decided to exercise the authority to buy back shares granted by the Annual General Meeting on 15 March 2021. The authority is valid until 15 March 2026 and covers a maximum of 22,400,000 shares. Purpose The purpose of the share buyback is to adjust the capital structure and meet obligations relating to the Group’s share-based incentive programmes. At the Annual General Meeting of DSV Panalpina A/S, a resolution will be proposed that any shares not used for hedging or the incentive programmes will be cancelled. Time frame The share buyback programme will run from 27 April 2021 to 28 July 2021 at the latest, both days inclusive. During this period, DSV Panalpina A/S will buy its own shares up to maximum of DKK 4,000 million in accordance with Regulation No. 596/2014...

Company Announcement No. 882 Selected key figures and ratios for the period 1 January – 31 March 2021(DKKm)     Q1 2021 Q1 2020         Key figures and ratios        Revenue     33,616 27,309Gross profit     7,785 6,684Operating profit (EBIT) before special items     3,067 1,566Profit after tax     2,329 331         Adjusted earnings for the period     2,390 755Adjusted free cash flow     1,690 915Conversion ratio     39.4% 23.4%Diluted adjusted earnings per share of DKK 1 for the last 12 months     33.7 19.0Jens Bjørn Andersen, Group CEO: “Today, we are proud to announce our agreement to unite with Agility’s Global Integrated Logistics. The combination of our two groups is a perfect match, and Global Integrated Logistics will add around 23% to DSV Panalpina’s annual revenue and strengthen...

–Long-term follow-up study to evaluate bone mineral density in women completing at least 20 weeks of treatment in Phase 3 PRIMROSE 1 or PRIMROSE 2 –   GENEVA, Switzerland and BOSTON, MA – April 27, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the initiation of the observational PRIMROSE 3 study. PRIMROSE 3 will evaluate long-term bone mineral density (BMD) in subjects who completed at least 20 weeks of treatment in the Phase 3 PRIMROSE 1 (US only) and PRIMROSE 2 (Europe and EU) studies. “GnRH antagonists are an exciting new therapeutic approach for the treatment of uterine fibroids. In the setting of dose-dependent reductions in estradiol, it is important to understand changes in bone mineral density...